HCPCS Level II code G0012 denotes the administration of an injectable pre-exposure prophylaxis (PrEP) medication for HIV prevention, given subcutaneously or intramuscularly. This code matters nationally as long-acting injectable PrEP expands clinical options for HIV prevention, affecting coverage determinations, billing workflows, and access in outpatient and ambulatory settings. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will gain a concise account of what G0012 represents clinically and operationally, plus an outline of payer coverage patterns and billing considerations relevant to ambulatory medication administration. The publication summarizes benchmarks where available, highlights recent policy updates influencing coverage of long-acting injectable PrEP, and provides clinical context about the service type and typical sites of service. Practical billing elements covered include the code’s intended use, common modifiers in payer practice (listed separately), and areas where payers commonly require documentation or prior authorization.

Intended for providers, billing professionals, and policy analysts, this summary helps stakeholders understand where G0012 fits into HIV prevention services nationally and what to expect in payer interactions and billing workflows.